Join Growin Stock Community!

禾榮科7799.TW Overview

TW StockBiotech. & Medical
(No presentation for 7799)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

禾榮科（7799）Overall Performance

禾榮科（7799）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

禾榮科（7799） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

禾榮科（7799）Key Information

禾榮科（7799）Profile

禾榮科（7799）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
14244.20
PB Ratio
6.50
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-379.50%
Net Margin
-9884.26%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
14244.20
PB Ratio
6.50
Price-to-FCF
-
Gross Margin
-379.50%
Net Margin
-9884.26%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

7799

禾榮科

503.00D

-8.35%

(-0.08)

  • When is 7799's latest earnings report released?

    The most recent financial report for 禾榮科 (7799) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 7799's short-term business performance and financial health. For the latest updates on 7799's earnings releases, visit this page regularly.

  • What is the operating profit of 7799?

    According to the latest financial report, 禾榮科 (7799) reported an Operating Profit of -233.52M with an Operating Margin of -6,637.81% this period, representing a decline of 204.31% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 7799's revenue growth?

    In the latest financial report, 禾榮科 (7799) announced revenue of 3.52M, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 7799 have?

    At the end of the period, 禾榮科 (7799) held Total Cash and Cash Equivalents of 11.16B, accounting for 0.92 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 7799 go with three margins increasing?

    In the latest report, 禾榮科 (7799) did not achieve the “three margins increasing” benchmark, with a gross margin of -56.54%%, operating margin of -6,637.81%%, and net margin of -6,589.45%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 7799's profit trajectory and future growth potential.

  • Is 7799's EPS continuing to grow?

    According to the past four quarterly reports, 禾榮科 (7799)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.6. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 7799?

    禾榮科 (7799)'s Free Cash Flow (FCF) for the period is -11B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 2,517.42% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.